ArticleBioPsychoSocial medicine2017

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.

Motoko Ida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.